Oral ganciclovir treatment in chronic hepatitis B virus infection: A pilot study

Journal of Hepatology

Volumn 31, Issue 2, 1999, Pages 210-214

  Hadziyannis, Stephanos J ^a   Manesis, Emanuel K ^a   Papakonstantinou, Anastasia ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

Author keywords

Ganciclovir, chronic hepatitis B; Nucleoside analogues, hepatitis B infection; Oral ganciclovir therapy

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; NUCLEOSIDE ANALOG;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DRUG SAFETY; DRUG USE; HEPATITIS B; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0032789959     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80215-3     Document Type: Article

References (26)

1. Locarnini S, Guo K, Lucas R, Gest I. Inhibition of HBV DNA replication by ganciclovir in patients with AIDS. [letter] Lancet. ii:1989;1225-1226.
2. Angus P, Richards M, Bowden S, Ireton J, Sinclair R, Jones R, et al. Combination antiviral therapy controls severe post-liver transplant recurrence of hepatitis B virus infection. J Gastroenterol Hepatol. 8:1993;353-357.
3. Yoshida EM, Wolber RA, Mahmood WA, Anderson FA, Scudamore CH, Erb SR. Attempted resolution of acute recurrent hepatitis B in a transplanted liver allograft by the administration of ganciclovir. Transplantation. 58:1994;956-958.
4. Anand BS, Yoffe B, Young JB. Ganciclovir treatment of active hepatitis B virus infection in a heart transplant patient. J Clin Gastroenterol. 22:1996;144-146.
5. Jamal H, Regenstein F, Farr G, Perrillo RP. Prolonged survival in fibrosing cholestatic hepatitis with long-term ganciclovir therapy. Am J Gastroenterol. 91:1996;1027-1030.
6. Gish RG, Lau JYN, Brooks L, Fang JWS, Steady SL, Imperial JC, et al. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology. 23:1996;1-7.
7. Wang Y, Bowden S, Shaw T, Civitico G, Chan Y, Qiao M, et al. Inhibition of duck hepatitis B virus replication in vivo by the nucleoside analogue ganciclovir (9-[2-hydroxyl-1- (hydroxymethyl)e-thoxymethyl] guanine). Antiviral Chem Chemother. 22:1991;107-114.
8. Luscombe C, Pedersen J, Uren E, Locarnini S. Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: effect on intrahepatic viral DNA, RNA and protein expression. Hepatology. 24:1996;766-773.
9. Anderson RD, Griffy KG, Jung D, Dorr A, Hulse JD, Smith RB. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000 mg/d dosing regimens in human immunodefficiency virus- and cytomegalovirus-seropositive patients. Clin Ther. 17:1995;425-432.
10. Tocci MJ, Livelli TJ, Perry HC, Crumpacker CS, Field AK. Effects of the nucleoside analogue 2′-nor-2′-deoxyguanosine on human cytomegalovirus replication. Antimirob Agents Chemother. 25:1984;247-252.
11. Drew WL, Miner R, Saleh E. Antiviral suseptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals. Clin Diagn Virol. 1:1993;179-185.
12. Drew WL, Ives D, Lalezari JP, Crumbacker C, Follansbee SE, Spector SA, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med. 333:1995;615-620.
13. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. 324:1991;1005-1011.
14. Hendricks DA, Stowe BJ, Hoo BS, Kolberg J, Irvine BD, Neuwald PD, et al. Quantification of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay. Am J Clin Pathol. 104:1995;537-546.
15. Hammerle T, Himmelsplach M, Dorner F, Falkner FG. A sensitive PCR assay for the quantitation of viral genome equivalents: human immunodeficiency virus type 1 (HIV-1) and hepatitis B virus (HBV). Arch Virol. 142:1997;1297-1306.
16. Armitage P, Berry G. Statistical Methods in Medical Research, 3rd ed. 1994;Blackwell Science Ltd, Oxford.
17. Norusis MJ. SPSS for Windows (version 8.0). 1998;SPSS Inc, Chicago, IL.
18. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 22:1995;696-699.
19. Kruining J, Heijtink RA, Schalm SW. Antiviral agents in hepatitis B virus transfected cell lines: inhibitory and cytotoxic effect related to time of treatment. J Hepatol. 22:1995;263-267.
20. McMillan JS, Shaw T, Angus PW, Locarnini SA. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology. 22:1995;36-43.
21. Crumpacker CS. Ganciclovir. N Engl J Med. 335:1996;721-729.
22. DeArmond B. Future directions in the management of cytomegalovirus infections. J Aquir Immune Defic Syndr. 4:(Suppl 1):1991;S53-S56.
23. Spector SA, Busch DF, Follansbee S, Squires K, Lalezari JP, Jacobson MI, et al. Pharmacokinetic, safety and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. J Infect Dis. 171:1995;1431-1437.
24. Shaw T, Amor P, Civitico G, Boyd M, Locarnini S. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob Agents Chemother. 38:1994;719-723.
25. Cheng YC, Huang EC, Lin JC, Mar EC, Pagano JS, Dutschman GE, et al. Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpes viruses in vitro and its mode of action against herpes simplex virus type 1. Proc Natl Acad Sci USA. 80:1983;2767-2770.
26. Drew L, Miner RC, Bush DF, Follansbee SE, Gullett J, Mehalko SG, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis. 163:1991;716-719.